After two rejections, the FDA finally approved AstraZeneca's potassium drug Lokelma, the drugmaker announced May 18.
Here are three things to know.
1. Lokelma is intended to treat patients with hyperkalemia, a condition involving elevated potassium levels in the blood.
2. AstraZeneca gained the rights to the drug through its $2.7 billion acquisition of ZS Pharma in 2015, according to Reuters.
3. Lokelma will compete with Vifor Pharma's drug Veltassa, also used to treat hyperkalemia.